hydroxychloroquine in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Abd-Elsalam, 2020 1.21 [0.36; 4.12]
Chen, 2020 0.56 [0.01; 30.20]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89]
HYCOVID, 2020 0.54 [0.21; 1.40]
NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78]
ORCHID, 2020 1.07 [0.54; 2.11]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
TEACH, 2020 1.07 [0.34; 3.37]
1.10 [0.99 ; 1.22 ] Abd-Elsalam, 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 2020, HYCOVID, 2020, NO COVID-19 (Lyngbakken), 2020, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020, TEACH, 2020 10 0% 8,065 moderate low deaths (time to event analysis only)detailed results RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
1.10 [0.99 ; 1.23 ] RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 2 0% 6,569 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.92 [0.61; 1.38]
TEACH, 2020 1.80 [0.62; 5.21]
1.07 [0.62 ; 1.85 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, TEACH, 2020 2 25% 458 moderate not evaluable clinical improvementdetailed results ORCHID, 2020 1.02 [0.73; 1.42]
1.02 [0.73 ; 1.42 ] ORCHID, 2020 1 0% 479 low not evaluable clinical improvement (14-day)detailed results Chen, 2020 0.56 [0.13; 2.48]
0.56 [0.13 ; 2.48 ] Chen, 2020 1 0% 33 moderate not evaluable death or ventilationdetailed results HYCOVID, 2020 1.12 [0.45; 2.79]
RECOVERY, 2020 1.14 [1.03; 1.27]
SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42]
1.14 [1.03 ; 1.25 ] HYCOVID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 3 0% 6,023 moderate not evaluable PCR-negative conversiondetailed results HC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75]
0.46 [0.04 ; 5.75 ] HC-nCoV (Shanghai), 2020 1 0% 30 moderate not evaluable PCR-negative conversion (14-day)detailed results Chen, 2020 1.42 [0.26; 7.76]
1.42 [0.26 ; 7.76 ] Chen, 2020 1 0% 33 moderate not evaluable ICU admissiondetailed results Abd-Elsalam, 2020 0.83 [0.35; 1.95]
0.83 [0.35 ; 1.95 ] Abd-Elsalam, 2020 1 0% 194 moderate not evaluable cardiac arrestdetailed results SOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49]
1.92 [0.35 ; 10.49 ] SOLIDARITY (WHO study) HCQ, 2020 1 0% 1,853 moderate not evaluable adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01]
ORCHID, 2020 1.26 [0.56; 2.84]
RECOVERY, 2020 1.36 [0.98; 1.90]
TEACH, 2020 1.16 [0.55; 2.42]
1.29 [0.98 ; 1.69 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 2020, ORCHID, 2020, RECOVERY, 2020, TEACH, 2020 5 0% 5,685 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2021-01-27 16:53 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 657
- roots T: 290
